Trial Profile
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2024 Planned End Date changed from 1 Aug 2023 to 1 Jun 2025.
- 18 Apr 2022 Results of two phase 2 studies (CTI; NCT02219178 & DFCI; NCT02441686) were published in the American Journal of Hematology.
- 11 Feb 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.